Currently Viewing:
Newsroom
Currently Reading
The Financial Burden of Parkinson Disease Is $52 Billion, More Than Double Previous Estimates
June 16, 2019 – Wallace Stephens
Evaluating Use of Bone-Modifying Agents to Treat Skeletal-Related Events in Cancer
June 15, 2019 – Laura Joszt
Isatuximab Combination Improves PFS in Relapsed, Refractory MM
June 15, 2019 – Samantha DiGrande
Sensory Processing Difficulties Worsen Quality of Life in Children With Migraine
June 15, 2019 – AJMC Staff
Are Daily Corticosteroids Necessary for Mild Asthma? Recent Study Suggests Otherwise
June 14, 2019 – Samantha DiGrande
Exploring Oncology Financial Toxicity, Cost of Care
June 14, 2019 – AJMC Staff
Attending to Psychosocial Concerns for Those With Epidermolysis Bullosa
June 14, 2019 – AJMC Staff
5 Takeaways From the ADA Scientific Sessions
June 14, 2019 – Mary Caffrey
AJMC® in the Press, June 14, 2019
June 14, 2019 – AJMC Staff

Damaged Immune Receptor Could Lead to More Severe Comorbidities in HIV, Study Finds

Samantha DiGrande
While treatment for HIV has made tremendous strides over the past few decades, many patients with the infection still struggle with comorbidities such as chronic inflammation, diabetes, and cardiovascular problems, among others. In a recent study, researchers at Michigan State University sought to understand why patients with HIV develop such complications.
While treatment for HIV has made tremendous strides over the past few decades, many patients with the infection still struggle with comorbidities such as chronic inflammation, diabetes, and cardiovascular problems, among others.

Researchers at Michigan State University sought to understand why patients with HIV develop such complications, in a study recently published in the Journal of Immunology.

Investigators studied the immune systems of both healthy patients and patients with HIV. Within the study, researchers tested patients’ blood by isolating their white blood cells and stimulating them with interferon alpha. The authors identified an immune receptor, SLAMF7, that had the ability to lower or “tone down” the body’s immune response when activated on monocytes.

After stimulating a patient’s white blood cells, researchers examined how SLAMF7 responded and found that it was unresponsive in certain patients with HIV who had more severe complications. However, researchers also noted that SLAMF7 increased the monocytes’ resistance to HIV by raising the level of the CCL3L1 protein, which makes it more difficult for the HIV virus to enter cells.

“When receptors need to turn immune cells on because of an infection, they bind to the cells and work with fellow receptors to activate the immune system. when signs of infection or inflammation go away, the receptors switch gears and turn off the immune response,” said lead study author, Patrick O’Connell, in a statement.

Often, clinicians treating a patient with HIV will find that the patient has malfunctioning receptors and their body isn’t able to shut off their own immune systems, which can leave the body in a chronic proinflammatory state. If there is overactivation, this could lead to autoimmune disorders where the body attacks its own tissues. Conversely, if there is underactivation, the body is unable to fight off infections. “HIV patients are different because they can experience both,” said O’Connell.

Future studies should look to understand the molecular mechanism of the SLAMF7 and the mechanism of action as that could eventually lead to new treatments that target immune activation. “These findings implicate the SLAMF7 receptor as an important regulator of [interferon alpha-driven] innate immune responses during HIV infection,” read the study.

Reference

O'Connell P, Pepelyayeva Y, Blake M, et al. SLAMF7 is a critical negative regulator of IFN-a-mediated CXCL10 production in chronic HIV infection. J Immunol. 2019;202(1):228-238. doi: 10.4049/jimmunol.1800847.

Related Articles

Researchers Propose Adding Viral Suppression Within 3 Months of HIV Diagnosis to HIV/AIDS Strategy
A Current Look at Managing HIV
Selecting a Therapeutic Regimen for HIV Treatment
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up